Lixia Yu
Zhejiang Chinese Medical University(CN)Jiangsu University(CN)Nanchang University(CN)Chinese Academy of Sciences(CN)Nantong University(CN)Affiliated Hospital of Nantong University(CN)Nantong Tumor Hospital(CN)First People's Hospital of Kunshan(CN)Nanjing Drum Tower Hospital(CN)Shanghai Institute of Materia Medica(CN)University of Chinese Academy of Sciences(CN)Nanjing University(CN)
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Immunotherapy and Immune Responses, Nanoparticle-Based Drug Delivery, Nanoplatforms for cancer theranostics, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers(2010)341 cited
- → CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients(2016)302 cited
- → Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles(2013)126 cited
- → The antitumor effect of novel docetaxel-loaded thermosensitive micelles(2008)125 cited
- → DOX/ICG Coencapsulated Liposome-Coated Thermosensitive Nanogels for NIR-Triggered Simultaneous Drug Release and Photothermal Effect(2018)109 cited
- → Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells(2008)106 cited